Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - tozinameranum, riltozinameranum - comirnaty® original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion für personen ab 18 jahren - suspension: tozinameranum 15 µg pro dosi, riltozinameranum 15 µg pro dosi, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diylis)bis(2-hexyldecanoas), 2-(polyethylenglycoli 2000)-n,n-ditetradecylacetamidum, 1,2-distearoyl-sn-glycero-3-phosphocholinum, cholesterolum, saccharum, trometamolum, trometamoli hydrochloridum, aqua ad iniectabile, pro dosi. - comirnaty original/omicron ba.1 15/15 µg pro dosis gebrauchsfertige injektionsdispersion ist indiziert für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus hervorgerufenen covid-19-erkrankung bei personen ab 18 jahren - les vaccins

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

moderna switzerland gmbh - imelasomeranum, elasomeranum - spikevax bivalent original / omicron - suspension: imelasomeranum 0.025 mg pro dosi, elasomeranum 0.025 mg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas pro dosi, cholesterolum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus pro dosi, trometamolum pro dosi, trometamoli hydrochloridum pro dosi, acidum aceticum pro dosi, natrii acetas pro dosi, saccharum pro dosi, aqua ad iniectabile, pro dosi. - spikevax bivalent original / omicron ist für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus verursachten coronavirus-2019-erkrankung (covid-19) bei personen ab 18 jahren indiziert. - les vaccins

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - nicotinum - wirkstoffhaltiges kaugummi mit original-aroma - nicotinum 2 mg à nicotini resinas, sont, antiox.: e 321, excipiens pour la préparation. - le soutien de l'arrêt du tabac - synthetika

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

jntl consumer health ii (switzerland) gmbh - nicotinum - wirkstoffhaltiges kaugummi mit original-aroma - nicotinum 4 mg pour nicotini resinas, sont de la couleur.: e 104, antiox.: e 321, excipiens pour la préparation. - le soutien de l'arrêt du tabac - synthetika

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

intergal pharma ireland ltd. - macrogol 6,563 g; bicarbonate de sodium 0,0893 g; chlorure de potassium 0,0251 g; chlorure de sodium 0,1754 g - poudre pour solution buvable - 6.9 g - macrogol 3.350 6563 mg; chlorure de potassium 25.1 mg; chlorure de sodium 175.4 mg; bicarbonate de sodium 89.3 mg - macrogol, combinations

Suisse - français - Swissmedic (Swiss Agency for Therapeutic Products)

moderna switzerland gmbh - imelasomeranum, elasomeranum - seringue préremplie - suspension: imelasomeranum 0.025 mg pro dosi, elasomeranum 0.025 mg pro dosi, heptadecan-9-ylis 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)-octanoas pro dosi, cholesterolum pro dosi, 1,2-distearoyl-sn-glycero-3-phosphocholinum pro dosi, 1,2-dimyristoyl-rac-glycero-3-polyethylenglycoli 2000 aether methylicus pro dosi, trometamolum pro dosi, trometamoli hydrochloridum pro dosi, acidum aceticum pro dosi, natrii acetas trihydricus pro dosi, saccharum pro dosi, aqua ad iniectabile, pro dosi. - spikevax bivalent original / omicron ist für die aktive immunisierung zur vorbeugung der durch das sars-cov-2-virus verursachten coronavirus-2019-erkrankung (covid-19) bei personen ab 18 jahren indiziert. - les vaccins

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norgine sa-nv - chlorure de sodium 0,1754 g; chlorure de potassium 0,0251 g; macrogol 6,563 g; bicarbonate de sodium 0,0893 g - poudre pour solution buvable - 6,9 g - macrogol 3.350 6563 mg; chlorure de potassium 25.1 mg; chlorure de sodium 175.4 mg; bicarbonate de sodium 89.3 mg - macrogol, combinations

Belgique - français - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

norgine sa-nv - bicarbonate de sodium 0,1786 g; chlorure de sodium 0,3508 g; chlorure de potassium 0,0502 g; macrogol 13,125 g - poudre pour solution buvable - 13,7 g - macrogol 3.350 13125 mg; chlorure de potassium 50.2 mg; bicarbonate de sodium 178.6 mg; chlorure de sodium 350.8 mg - macrogol, combinations

Union européenne - français - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccins - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. l'utilisation de ce vaccin doit être en conformité avec les recommandations officielles.

Union européenne - français - EMA (European Medicines Agency)

glaxosmithkline trading services limited - sotrovimab - covid-19 virus infection - des sérums et immunoglobulines, - xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (covid-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe covid-19.